DSV Fund, a hedge fund dedicated to the Bittensor ecosystem, has completed an OTC investment in SafeScan AI (SN76), marking a significant step forward for decentralized AI in healthcare. The fundβs entry highlights how blockchain-incentivized projects are beginning to shape the future of early cancer detection.
SafeScan AI, founded by Polish entrepreneurs Mateusz WoΕΊniak and Wojciech Jurkowlaniec, uses Bittensorβs global network to crowdsource and refine AI models for skin cancer diagnostics, beginning with melanoma. Early real-world validation in dermatology clinics shows that SafeScanβs decentralized models outperform leading traditional baselines, creating the potential for meaningful improvements in early detection accuracy.
How SafeScan Works: A Global, Incentive-Driven AI Challenge
SafeScan functions as an open marketplace where
β’ Medical partners contribute anonymized clinical data
β’ AI developers (βminersβ) submit diagnostic models
β’ Validators score models every 24 hours based on accuracy and reliability
β’ Top performers earn $TAO, driving continuous improvement
This dynamic has already attracted researchers and medical collaborators worldwide. Even a 1% improvement in diagnostic accuracy could save thousands of lives annually, according to WHO estimates on skin-cancer outcomes.
Why DSV Fund Invested
The investment reflects DSVβs conviction that SN76 is one of the most undervalued high-impact subnets in Bittensor. DSV has invested in SafeScan because their melanoma model is being tested inside real dermatology clinics and already beats state-of-the-art baselines.
With Bittensor now hosting 128 specialized subnets, SafeScan stands out as a powerful example of decentralized AI applied to public health. DSVβs investment signals a growing belief that SN76 could become a pivotal force in global cancer screening as clinical trials expand.
Be the first to comment